Stock Market Reviews

GLUE (Monte Rosa Therapeutics, Inc.) News

Get the latest news, insights, and market updates on GLUE (Monte Rosa Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
  Kura Oncology (KURA) delivered earnings and revenue surprises of -28.67% and -41.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
  Mar 5, 2026 - $GLUE
• Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
  In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions Combination of MRT-2359 a
  Feb 24, 2026 - $GLUE
• Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
  BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to present, March 2, 2026, at 3:10 p.m. ETBarclays 28th Annual Global Healthcare Conference (Miami, FL) – Filip Jan
  Feb 23, 2026 - $GLUE
• NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
  NeoGenomics (NEO) delivered earnings and revenue surprises of +57.90% and +0.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
  Feb 17, 2026 - $GLUE
• Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains
  Key Insights Significantly high institutional ownership implies Monte Rosa Therapeutics' stock price is sensitive to...
  Feb 6, 2026 - $GLUE
• Staar Surgical, Alumis, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Jan 17, 2026 - $GLUE
• Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum
  Monte Rosa Therapeutics (GLUE) drew fresh attention after reporting strong interim Phase 1 results for MRT-8102, its NEK7-directed molecular glue degrader. The data showed rapid, sustained reductions in inflammatory markers in subjects with elevated cardiovascular risk and a favorable safety profile. See our latest analysis for Monte Rosa Therapeutics. That clinical update has arrived during a period of sharp price swings, with a 7 day share price return of 58.59% and a 90 day share price...
  Jan 10, 2026 - $GLUE
• Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
  BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price
  Jan 9, 2026 - $GLUE
• Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable
  Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
  Jan 8, 2026 - $GLUE
• GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
  Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.
  Jan 8, 2026 - $GLUE